Rethinking pulmonary arterial hypertension care: the role of dual therapy in patients with cardiovascular comorbidities
- PMID: 40335084
- DOI: 10.1183/13993003.00273-2025
Rethinking pulmonary arterial hypertension care: the role of dual therapy in patients with cardiovascular comorbidities
Conflict of interest statement
Conflict of interest: C. Hjalmarsson is a consultant and advisor for Johnson & Johnson, AOP Health/OrphaCare and MSD, clinical trial site PI or SI for Johnson & Johnson, United Therapeutics, Boehringer Ingelheim, Acceleron and MSD, and a recipient of unrestricted research grants from Johnson & Johnson and MSD. S. Sahay is a consultant and advisor for Merck, United Therapeutics, Keros, Morphic, Pulmovant and Gossamer Bio, clinical trial site PI for United Therapeutics, Keros and Pulmovant, and a data and safety monitoring board chair and member for NIH funded studies.
Comment on
-
Initial therapy in patients with pulmonary arterial hypertension and cardiovascular comorbidities.Eur Respir J. 2025 May 6;65(5):2400895. doi: 10.1183/13993003.00895-2024. Print 2025 May. Eur Respir J. 2025. PMID: 39884763